Table 4.
Treatment-related adverse events
| n(%) | All grade | Grade 3–4 | ||||
|---|---|---|---|---|---|---|
| TACE-TC(n = 46) | TACE-T(n = 42) | P | TACE-TC(n = 46) | TACE-T(n = 42) | P | |
| Hypertension | 10(21.7) | 13(31.0) | 0.326 | 2(4.3) | 4(9.5) | 0.419 |
| Diarrhea | 8(17.4) | 7(16.7) | 0.928 | 1(2.1) | 2(4.8) | 0.604 |
| Appetite decreased | 7(15.2) | 5(11.9) | 0.651 | 0 | 0 | - |
| Fatigue | 5(10.9) | 3(7.1) | 0.716 | 0 | 0 | - |
| RCCEP | 11(23.9) | 0 | 0.001 | 0 | 0 | - |
| Hypothyroidism | 4(8.6) | 0 | 0.118 | 0 | 0 | - |
| Hoarseness | 0 | 1(2.4) | 0.477 | 0 | 0 | - |
| Hand–foot skin reaction | 4(8.6) | 9(21.4) | 0.133 | 1(2.1) | 2(4.8) | 0.604 |
| Hemorrhagic cystitis | 1(2.2) | 0 | 1.000 | 0 | 0 | - |
| Thrombocytopaenia | 12(26.1) | 14(33.3) | 0.457 | 3(6.5) | 2(4.8) | 1.000 |
| Neutropaenia | 14(30.4) | 10(23.8) | 0.486 | 0 | 1(2.4) | 0.477 |
| Decreased WBC count | 11(23.9) | 9(21.4) | 0.781 | 1(2.1) | 0 | 1.000 |
| Lymphocytopenia | 12(26.1) | 10(23.8) | 0.805 | 2(4.3) | 0 | 0.495 |
| Elevated AST | 19(41.3) | 20(47.6) | 0.551 | 4(8.7) | 5(11.9) | 0.731 |
| Elevated ALT | 14(30.4) | 13(31.0) | 0.958 | 2(4.3) | 0 | 0.495 |
| Elevated bilirubin | 21(45.7) | 18(42.9) | 0.792 | 0 | 3(7.1) | 0.105 |
RCCEP, Reactive cutaneous capillary endothelial proliferation; WBC, white blood cell; ALT, alanine amiotransferase; AST, aspartate transaminase.